99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of Acer Therapeutics Inc. Investors. Click "Join this Class Action" above.

Attorneys

Acer Therapeutics Inc.

Join Class Action »

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Acer Therapeutics Inc. (NASDAQ: ACER) from September 25, 2017 through June 24, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Acer investors under the federal securities laws.

If you bought Acer securities between September 25, 2017 and June 24, 2019 and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Acer Therapeutics Inc. – ACER

New York, N.Y., July 8, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Acer Therapeutics Inc. (NASDAQ: ACER) from September 25, 2017 through June 24, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Acer investors under the federal securities laws.

To join the Acer class action, go to http://zhanginvestorlaw.com/cases/acer-therapeutics-inc/ or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Acer lacked sufficient data to support filing EDSIVO’s New Drug Application (“NDA”) with the FDA for the treatment of vEDS; (ii) the Ong Trial, a 2004 study Acer heavily relied on its submission of EDSIVO’s NDA, was an inadequate and ill-controlled clinical study by FDA standards, and was comprised of an insufficiently small group size to support EDSIVO’s NDA; (iii) consequently, the FDA would likely reject EDSIVO’s NDA; and (3) as a result, defendants’ statements about Acer’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 30, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/acer-therapeutics-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.
——————————-